Arlington Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$35.1K Buy
+610
New +$35K ﹤0.01% 310
2025
Q2
Sell
-274
Closed -$16.7K 707
2025
Q1
$16.7K Sell
274
-117
-30% -$6.82K ﹤0.01% 474
2024
Q4
$22.1K Buy
391
+117
+43% +$6.54K ﹤0.01% 417
2024
Q3
$14.2K Sell
274
-1,582
-85% -$74.2K ﹤0.01% 427
2024
Q2
$77.1K Buy
1,856
+900
+94% +$40.3K 0.02% 285
2024
Q1
$51.8K Sell
956
-100
-9% -$5.09K 0.01% 282
2023
Q4
$54.2K Buy
+1,056
New +$55.4K 0.02% 279

Other funds holding BMY

Arlington Trust's BMY Position: Q2 2026 in Review

Arlington Trust opened a new position in Bristol-Myers Squibb (BMY) in Q2 2026: 610 shares worth $35.1K. The stake represents ﹤0.01% of the portfolio and ranks #310 among its holdings. This is a return to the name: Arlington Trust previously reported a position in BMY as recently as Q1 2025.

Arlington Trust first reported a position in BMY in Q4 2023 and has held it in 7 quarters since. The position peaked at $77.1K in Q2 2024. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Arlington Trust held 610 shares of Bristol-Myers Squibb worth $35.1K as of Q2 2026.
  • Bristol-Myers Squibb was a new Arlington Trust position in Q2 2026.
  • Bristol-Myers Squibb made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #310 holding.
  • Arlington Trust first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 7 quarters since.
  • Arlington Trust's Bristol-Myers Squibb position peaked at $77.1K in Q2 2024.
  • 2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.